Finally, we investigated the effect of AURKA on chemotherapy resistance and found that AURKA overexpression could antagonize the toxicity of doxorubicin and paclitaxel drugs, and AURKA siRNA 1/2 could enhance the antitumor activity of paclitaxel and doxorubicin drugs in human breast cancer cell lines (Figure 5J,K). Here, AURKA is linked to breast carcinoma.